Annual report pursuant to Section 13 and 15(d)

Note 14- Income Taxes (Tables)

v3.22.1
Note 14- Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Notes Tables  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   

As of December 31,

 
   

2021

   

2020

 

Deferred tax assets:

               

Net operating loss carryforwards

  $ 36,793,074     $ 34,365,098  

R&D credit carryforwards

    9,501,299       9,301,709  

Stock compensation

    481,098       419,654  

Intangibles

    567,213       616,926  

Disallowed interest expense

    851,247       852,338  

Temporary differences

    305,974       267,312  

Deferred tax assets before valuation allowance

    48,499,905       45,823,037  

Valuation allowance

    (48,499,905

)

    (45,823,037

)

Net deferred tax assets

  $     $  
Summary of Tax Credit Carryforwards [Table Text Block]
         

As of December 31, 2021

 

Generated

 

Expiration

   

U.S. Net

Operating

Loss

Carryforwards

   

U.S. R&D

Credit

Carryforwards

 

2001

 

2021

    $     $ 39,128  

2002

 

2022

            5,350  

2003

 

2023

            2,905  

2004

 

2024

            22,861  

2005

 

2025

            218,332  

2006

 

2026

            365,541  

2007

 

2027

            342,898  

2008

 

2028

            531,539  

2009

 

2029

            596,843  

2010

 

2030

            1,094,449  

2011

 

2031

            1,950,744  

2012

 

2032

      18,898,490       468,008  

2013

 

2033

      37,450,522       681,772  

2014

 

2034

      34,088,874       816,116  

2015

 

2035

      25,073,846       492,732  

2016

 

2036

      15,581,209       262,257  

2017

 

2037

            387,892  

2018

  N/A             197,547  

2019

  N/A       11,245,808       213,065  

2020

  N/A       11,018,478       222,842  

2021

  N/A       10,746,123       238,717  

Total carryforwards

    $ 164,103,350     $ 9,112,411  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   

2021

   

2020

 
   

Amount

   

%

   

Amount

   

%

 

Benefit at statutory rate

  $ (2,460,126

)

    (21.0

)%

  $ (2,390,972

)

    (21.0

)%

Adjustments to valuation allowance

    2,676,868       22.9

%

    2,521,625       22.1

%

Adjustments to R&D credit carryforwards

    (199,589

)

    (1.7

)%

    (151,129

)

    (1.3

)%

Permanent items and other

    (1,110

)

    (0.1

)%

    20,476       0.2

%

Provision (benefit) per financial statements

  $ 16,043             $